Business
Mesoblast (ASX:MSB) and Novartis to commercialise remestemcel-L for ARDS – The Market Herald
Mesoblast (ASX:MSB) has entered an exclusive licence and collaboration agreement with Novartis to commercialise Mesoblast’s remestemcel-L therapy drug.
- Stem cell researcher Mesoblast (MSB) has entered a licence and collaboration agreement with Novartis to commercialise its remestemcel-L therapy drug
- Novartis is a Swiss-based pharmaceutical company with nearly two decades of experience in delivering products to help people with respiratory issues
- The companies will initially target remestemcel-L on treating COVID-19 related and non-COVID-19 related acute respiratory distress syndrome (ARDS)
- The drug is being used in a 300-patient COVID-19 ARDS, study…
Continue Reading
-
General20 hours agoAustralia loses ODI series to South Africa with defeat in second game in Mackay
-
General18 hours agoEveryday AI use brings a hidden climate cost
-
Noosa News23 hours agoBoat crash in Helensvale on the Gold Coast leaves man with life-threatening burns and another one injured
-
Noosa News22 hours agoBrisbane bands unite to help bassist’s cancer fight